Condition: Locally Advanced Unresectable or Metastatic Solid Tumors · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This is a Phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of IBI354 (study drug), and to explore and confirm the efficacy, safety and tolerability of IBI354 in subjects with locally advanced unresectable or metastatic solid tumors.
This description comes directly from the study's public registry record.
yuan lei · 8610-68585566 · yuan.lei@innoventbio.com
Always discuss trial participation with your own doctor first.
| Scientia Clinical Research Ltd | Randwick, New South Wales, Australia | Completed |
| Westmead Hospital | Sydney, New South Wales, Australia | Completed |
| Sunshine Coast University Private Hospital | Sunshine Coast, Queensland, Australia | Completed |
| Monash Health | Clayton, Victoria, Australia | Completed |
| Peking University Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Affiliated Cancer Hospital of Chongqing University | Chongqing, Chongqing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05636215